These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 29570299)
1. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment. Zou Y; Xia Y; Meng F; Zhang J; Zhong Z Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299 [TBL] [Abstract][Full Text] [Related]
2. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307 [TBL] [Abstract][Full Text] [Related]
3. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx? Zou Y; Meng F; Deng C; Zhong Z J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664 [TBL] [Abstract][Full Text] [Related]
4. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765 [TBL] [Abstract][Full Text] [Related]
6. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo. Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618 [TBL] [Abstract][Full Text] [Related]
7. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009 [TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
9. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor. Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533 [TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192 [TBL] [Abstract][Full Text] [Related]
11. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964 [TBL] [Abstract][Full Text] [Related]
12. CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice. Soleimani A; Mirzavi F; Nikoofal-Sahlabadi S; Nikpoor AR; Taghizadeh B; Barati M; Soukhtanloo M; Jaafari MR Sci Rep; 2022 Jun; 12(1):10423. PubMed ID: 35729230 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer. Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597 [TBL] [Abstract][Full Text] [Related]
14. Integrin α Zhou B; Li M; Xu X; Yang L; Ye M; Chen Y; Peng J; Xiao L; Wang L; Huang S; Zhang L; Lin Q; Zhang Z Mol Pharm; 2021 Jul; 18(7):2634-2646. PubMed ID: 34134485 [TBL] [Abstract][Full Text] [Related]
15. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276 [TBL] [Abstract][Full Text] [Related]
16. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice. Ouyang J; Jiang Y; Deng C; Zhong Z; Lan Q Int J Nanomedicine; 2021; 16():4105-4115. PubMed ID: 34163162 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes. Arima H; Hagiwara Y; Hirayama F; Uekama K J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681 [TBL] [Abstract][Full Text] [Related]
19. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899 [TBL] [Abstract][Full Text] [Related]
20. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Fan M; Yang D; Liang X; Ao J; Li Z; Wang H; Shi B Biomed Pharmacother; 2015 Mar; 70():268-73. PubMed ID: 25776511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]